Compare Novavax Inc (NVAX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Veritone Inc — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Veritone Inc trades at $1.53 (market cap $138.04M). The key difference: Novavax Inc is far larger — about 9.5× Veritone Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VERI | |
|---|---|---|
Market Cap | $1.31B | $138.04M |
Sector | Health | Technology |
52-Week High | $11.19 | $8.39 |
52-Week Low | $6.22 | $1.00 |
Enterprise Value | $889.30M | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Veritone (VERI) trades at $1.52, up 5.56% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, though revenue remains around $90-92 million. Recent news highlights partnerships in AI and public safety, but the stock faces headwinds from a securities class action lawsuit with a July 20, 2026 deadline.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold ratings, but persistent losses and legal risks overshadow growth initiatives. Investment opportunity hinges on Veritone's ability to monetize its AI solutions and achieve profitability, while key risks include ongoing litigation and competitive pressures in the enterprise AI space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
